Psoriasis Pipeline Insight 2021 | Latest Advancements in Clinical Trials to Improve Treatment

Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping, as many prominent players such as Abbvie, Jannsen, Dermavant Sciences, UCB, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Arcutis Biotherapeutics, Amgen, Mylan, Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline, Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Biocad, Torrent Pharmaceuticals, Alvotech, Maruho Co., Ltd., Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Can-Fite Biopharma, MetrioPharm, Provectus Pharmaceuticals, Sienna Biopharmaceuticals and many others are developing Psoriasis therapies.

Los Angeles, USA , March 02, 2021 (GLOBE NEWSWIRE) -- Psoriasis Pipeline Insight 2021 | Latest Advancements in Clinical Trials to Improve Treatment

Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping, as many prominent players such as Abbvie, Jannsen, Dermavant Sciences, UCB, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Arcutis Biotherapeutics, Amgen, Mylan, Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline, Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Biocad, Torrent Pharmaceuticals, Alvotech, Maruho Co., Ltd., Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Can-Fite Biopharma, MetrioPharm, Provectus Pharmaceuticals, Sienna Biopharmaceuticals and many others are developing Psoriasis therapies.

DelveInsight’s “Psoriasis Pipeline Insight'' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Psoriasis pipeline landscapes. It comprises Psoriasis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Psoriasis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Psoriasis pipeline products.

Some of the important features of the Psoriasis Pipeline Report

• Psoriasis Pipeline seems to be robust as more than 20 molecules are in the registration/pre-registration phase, around 15 molecules are in Phase III, around 40 molecules are in Phase II, around 35 molecules are in Phase I/II or Phase I and around 15 molecules are in Preclinical Phase.

• The current Psoriasis pipeline features Biologics, Topical & Oral, and therapeutic candidates, which are being designed to be delivered with specially designed delivery vehicles. Most of the Psoriasis pipeline drugs are Biologics /Oral.

• Biologics have given patients the possibility of complete psoriasis clearance and control of their psoriatic arthritis (PsA), which a major unmet need of Psoriasis treatment. Newer biologics offer unprecedented efficacy & also provide lengthy remissions.

• The launch of various biologic therapies is expected in the next 3-5 years for the Psoriasis treatment.

Request for sample pages @ Psoriasis Clinical Trial Insight

Psoriasis is a chronic, immune-mediated inflammatory skin disease, which is characterized by the presence of papules and plaques occurring mainly on the elbows, knees, scalp, and lower back but is not restricted to these areas.

There is no cure for Psoriasis; however, there are multiple effective treatment options; topical therapy is the standard of care for treatment.

Psoriasis Pipeline Drugs

S.No.	Drug	Company	Phase	Product format
1	MYL-1401A	Mylan	Registered	Biologic
2	Abrilada	Pfizer	Registered	Biologic
3	Roflumiast	Arcutis Biotherapeutics	Phase III	Topical
4	ABP-654	Amgen	Phase III	Biologic
5	BMS-986165	Bristol-Myers Squibb	Phase III	Oral
6	Piclidenoson	Can-Fite Biopharma	Phase III	Oral
7	SNA021	Santalis Pharmaceuticals	Phase II	Topical
8	SNA 120	Sienna Biopharmaceuticals	Phase II	Topical
9	UHE-105	Therapeutics Inc.	Phase II	Topical
10	MP1032	MetrioPharm	Phase II	Oral
11	SCD-044	Sun Pharmaceutical Industries Limited	Phase II	Oral
12	PF-06826647	Pfizer	Phase II	Oral
13	M1095	Avillion LLP	Phase II	Intravenous
14	NP000888	Galderma R&D	Phase II	Topical
15	LEO 29102	LEO Pharma	Phase II	Topical
16	JNJ-38518168	Janssen Research & Development, LLC	Phase II	Oral
19	TAB08	Theramab LLC	Phase I/II	Intravenous
20	ESR-114	Escalier Biosciences	Phase I/II	Topical
21	SCB-808	Clover Biopharmaceuticals	Phase I	Subcutaneous
22	ABBV-157	Abbvie	Phase I	Oral
23	AK111	Akesobio Australia Pty Ltd	Phase I	Subcutaneous

For further product profiles, request @ Psoriasis Pipeline Landscape

Scope of Psoriasis Pipeline Drug Insight

• Coverage: Global

• Major Players: 80+ Key Players

• Prominent Players: Abbvie, Jannsen, Dermavant Sciences, UCB, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Arcutis Biotherapeutics, Amgen, Mylan, Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline, Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Biocad, Torrent Pharmaceuticals, Alvotech, Maruho Co., Ltd., Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Can-Fite Biopharma, MetrioPharm, Provectus Pharmaceuticals, Sienna Biopharmaceuticals and many others.

• Key Drugs Profiles: 80+ Products

• Phases:

• Psoriasis Therapies Late-stage (Phase III)

• Psoriasis Therapies (Phase II)

• Psoriasis Therapies (Phase I)

• Psoriasis Therapies Pre-clinical stage and Discovery candidates

• Discontinued and Inactive candidates

• Therapies:

• Cell Therapy

• Monoclonal Antibodies

• Protein

• Small Molecule

• Route of Administration:

• Intramuscular

• Intravenous

• Oral

• Parental

• Topical

• Transdermal

• Mechanism of Action:

• Immunosuppressants

• Tumour necrosis factor alpha inhibitors

• Aryl hydrocarbon receptor agonists

• IL17F protein inhibitors

• Interleukin-23 subunit p19 inhibitors

• Interleukin 12 inhibitors

• Interleukin 23 inhibitors
  
  

Key Questions regarding Current Psoriasis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report

• What are the current options for Psoriasis treatment?

• How many companies are developing therapies for the treatment of Psoriasis?

• How many Psoriasis emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Psoriasis?

• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Psoriasis market?

• Which are the dormant and discontinued products and the reasons for the same?

• What is the unmet need for current therapies for the treatment of Psoriasis?

• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Psoriasis therapies?

• What are the key designations that have been granted for the emerging therapies for Psoriasis?

• How many patents are granted and pending for the emerging therapies for the treatment of Psoriasis?

Table of Contents

1	Psoriasis Report Introduction
2	Psoriasis Overview
3	Psoriasis Current Treatment Patterns
4	Psoriasis Analytical Perspective
5	Psoriasis Pipeline Therapeutic Assessment
6	Psoriasis Late Stage Products (Phase III)
7	Psoriasis Mid Stage Products (Phase II)
8	Psoriasis Pre-clinical Products and Discovery Stage Products
9	Psoriasis Inactive Products
10	Psoriasis Dormant Products
11	Psoriasis Discontinued Products
12	Psoriasis Product Profiles
13	Psoriasis Key Companies
14	Psoriasis Key Products
15	Psoriasis Unmet Needs
16	Psoriasis Future Perspectives
17	Psoriasis Analyst Views
18	Appendix
19	Report Methodology
20	About DelveInsight

Get customized pipeline report @ Psoriasis Drug Treatment

Related Reports

• Psoriasis Market Analysis

DelveInsight's Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Psoriasis Epidemiology Forecast Analysis

DelveInsight's Psoriasis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Psoriasis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• Chronic Plaque Psoriasis Market Analysis

DelveInsight's Chronic Plaque Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Mild To Moderate Plaque Psoriasis Market Analysis

DelveInsight's Mild To Moderate Plaque Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Moderate Psoriasis Market Analysis

DelveInsight's Moderate Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Phototherapies for Psoriasis Market Analysis

DelveInsight's Phototherapies for Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Plaque Psoriasis Market Analysis

DelveInsight's Plaque Psoriasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

• Psoriasis Vulgaris Market Analysis

DelveInsight's Psoriasis Vulgaris - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

CONTACT: Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com